TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alberta Clinical Trial in Optimizing Hypertension: The RxAction Study
Brief Summary: The purpose of this study is to evaluate the effect of enhanced pharmacist care (patient identification, assessment, education, prescribing/titration of antihypertensive medications and close follow-up) on systolic blood pressure (BP) reduction in patients with poorly controlled hypertension in the community setting.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Enhanced pharmacist care; Type: EXPERIMENTAL; Interventions: Other: Enhanced pharmacist care | Intervention Type: OTHER; Name: Enhanced pharmacist care; Assigned to Arm(s): Enhanced pharmacist care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: misoprostol by midwife; Type: OTHER; Interventions: Other: misoprostol by midwife | Arm Label: Misoprostol by physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: misoprostol by midwife; Assigned to Arm(s): misoprostol by midwife
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Monitoring by an HIV-trained medical doctor, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Stavudine | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Monitoring by an HIV-trained primary care nurse, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Stavudine | Intervention Type: BEHAVIORAL; Name: Monitoring by an HIV-trained medical doctor; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Monitoring by an HIV-trained primary care nurse; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): A, B
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Physician/Pharmacist Collaborative Teams | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physician/Pharmacist Collaborative Teams; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Toronto Prehospital Hypertonic Resuscitation Head Injury and Multi Organ Dysfunction Trial
Brief Summary: This clinical trial will evaluate the ease of conducting a randomized trial on patients with severe head injury who are cared for by paramedics in the out of hospital setting. The trial will compare two different kinds of fluids that are commonly used to elevate blood pressure and minimize the impact of the brain injury. The two solutions are a salt solution of different concentrations. One is a normal saline solution similar to the consistency of human blood and the other is a higher concentration mixed with a sugar that helps to keep the solution in the blood stream longer. This study is conducted without patient consent at the time of the study enrolment. The study will report on whether this trial is feasible in the out of hospital setting before launching into a larger definitive trial.


Options:
A: Arm Label: Voluven® Arm; Type: EXPERIMENTAL; Interventions: Drug: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®" | Arm Label: 0.9 % NaCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9 % NaCl | Intervention Type: DRUG; Name: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®"; Assigned to Arm(s): Voluven® Arm | Intervention Type: DRUG; Name: 0.9 % NaCl; Assigned to Arm(s): 0.9 % NaCl
B: Arm Label: 1 Normal Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Normal Saline | Arm Label: 2 - hypertonic saline mixed with dextran; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline mixed with dextran | Intervention Type: DRUG; Name: hypertonic saline mixed with dextran; Assigned to Arm(s): 2 - hypertonic saline mixed with dextran | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): 1 Normal Saline
C: Intervention Type: DRUG; Name: Hypertonic Saline-Dextran Solution; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lactated Ringer's Solution; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: 10% Hemohes® (10% Hydroxyethyl starch); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sterofundin® (Ringer lactate solution); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Actrapid® (Insulin); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action Plan to Enhance Self-management and Early Detection of Exacerbations in COPD Patients; A Multicenter RCT (ACZiE)
Brief Summary: The purpose of this randomized controlled trial is to evaluate the hypothesis that the 'written' action plan, a self-management tool developed by the project group, enhances early detection and prompt action measures and consequently isbeneficial in exacerbation outcome (i.e., health status recovery time).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: case management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): 2
B: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
C: Intervention Type: BEHAVIORAL; Name: Intermediate care package; Assigned to Arm(s): N/A
D: Arm Label: 1 Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Action plan | Intervention Type: BEHAVIORAL; Name: Action plan; Assigned to Arm(s): 2 Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action Plan to Enhance Self-management and Early Detection of Exacerbations in COPD Patients; A Multicenter RCT (ACZiE)
Brief Summary: The purpose of this randomized controlled trial is to evaluate the hypothesis that the 'written' action plan, a self-management tool developed by the project group, enhances early detection and prompt action measures and consequently isbeneficial in exacerbation outcome (i.e., health status recovery time).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Home based pulmonary rehabilitation with exercise | Arm Label: exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Home based pulmonary rehabilitation with exercise | Intervention Type: OTHER; Name: Home based pulmonary rehabilitation with exercise; Assigned to Arm(s): Placebo, exercise
B: Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine
C: Arm Label: 1 Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Action plan | Intervention Type: BEHAVIORAL; Name: Action plan; Assigned to Arm(s): 2 Intervention
D: Arm Label: 1 Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported self management training and support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Supported self management training and support | Intervention Type: BEHAVIORAL; Name: Supported self management training and support; Assigned to Arm(s): 1 Intervention group, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action Plan to Enhance Self-management and Early Detection of Exacerbations in COPD Patients; A Multicenter RCT (ACZiE)
Brief Summary: The purpose of this randomized controlled trial is to evaluate the hypothesis that the 'written' action plan, a self-management tool developed by the project group, enhances early detection and prompt action measures and consequently isbeneficial in exacerbation outcome (i.e., health status recovery time).


Options:
A: Arm Label: 1 Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Action plan | Intervention Type: BEHAVIORAL; Name: Action plan; Assigned to Arm(s): 2 Intervention
B: Arm Label: COPD Web; Type: EXPERIMENTAL; Interventions: Behavioral: COPD Web | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: COPD Web; Assigned to Arm(s): COPD Web
C: Arm Label: Fixed respiratory rehabilitation program(A); Type: EXPERIMENTAL; Interventions: Other: Fixed respiratory rehabilitation | Arm Label: Mixed respiratory rehabilitation program(B); Type: EXPERIMENTAL; Interventions: Other: Fixed respiratory rehabilitation, Other: Responsive respiratory rehabilitation | Arm Label: Control(C); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Fixed respiratory rehabilitation; Assigned to Arm(s): Fixed respiratory rehabilitation program(A), Mixed respiratory rehabilitation program(B) | Intervention Type: OTHER; Name: Responsive respiratory rehabilitation; Assigned to Arm(s): Mixed respiratory rehabilitation program(B)
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mobile phone technology | Intervention Type: BEHAVIORAL; Name: Mobile phone technology; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Brief Summary: This study is designed to assess the safety and efficacy of RAD001 monotherapy in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy.


Options:
A: Arm Label: Everolimus + BSC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Best Supportive Care (BSC) | Arm Label: Placebo + BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus placebo, Drug: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + BSC | Intervention Type: DRUG; Name: Everolimus placebo; Assigned to Arm(s): Placebo + BSC | Intervention Type: DRUG; Name: Best Supportive Care (BSC); Assigned to Arm(s): Everolimus + BSC, Placebo + BSC
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: docetaxel + S-1 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-1 | Intervention Type: DRUG; Name: docetaxel + S-1; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: S-1; Assigned to Arm(s): 2
C: Arm Label: IP Paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: IP Paclitaxel | Intervention Type: DRUG; Name: IP Paclitaxel; Assigned to Arm(s): IP Paclitaxel
D: Arm Label: ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: ramucirumab, Other: Best Supportive Care (BSC) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: ramucirumab; Assigned to Arm(s): ramucirumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Placebo, ramucirumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Vitamin D Supplementation in Winter-related, Childhood Atopic Dermatitis
Brief Summary: The goal of this clinical trial is to investigate the therapeutic role of vitamin D supplementation in a subset of patients with atopic dermatitis (AD): children with disease onset or worsening in the winter. The investigators hypothesis is that (1) vitamin D supplementation in patients with either wintertime onset or exacerbation of AD will improve Eczema Area and Severity Index (EASI) scores, and (2) vitamin D supplementation will improve the Investigator's Global Assessment.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: multiple micronutrients; Assigned to Arm(s): N/A
B: Arm Label: Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Study drug containing zinc alone; Type: EXPERIMENTAL; Interventions: Drug: Zinc | Arm Label: Study drug Micronutrient without zinc; Type: EXPERIMENTAL; Interventions: Drug: Micronutrient without zinc | Arm Label: Study drug Micronutrient with zinc; Type: EXPERIMENTAL; Interventions: Drug: Micronutrient with zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): Study drug containing zinc alone | Intervention Type: DRUG; Name: Micronutrient without zinc; Assigned to Arm(s): Study drug Micronutrient without zinc | Intervention Type: DRUG; Name: Micronutrient with zinc; Assigned to Arm(s): Study drug Micronutrient with zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Vitamin D Supplementation in Winter-related, Childhood Atopic Dermatitis
Brief Summary: The goal of this clinical trial is to investigate the therapeutic role of vitamin D supplementation in a subset of patients with atopic dermatitis (AD): children with disease onset or worsening in the winter. The investigators hypothesis is that (1) vitamin D supplementation in patients with either wintertime onset or exacerbation of AD will improve Eczema Area and Severity Index (EASI) scores, and (2) vitamin D supplementation will improve the Investigator's Global Assessment.


Options:
A: Arm Label: 400 IU Vitamin D3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol (D3) or ergocalciferol (D2) | Arm Label: 400 IU Vitamin D2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol (D3) or ergocalciferol (D2) | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol (D3) or ergocalciferol (D2); Assigned to Arm(s): 400 IU Vitamin D2, 400 IU Vitamin D3
B: Arm Label: Devit-3 Oral Drop 400 IU; Type: OTHER; Interventions: Drug: Devit-3 Oral Drop | Arm Label: Devit-3 Oral Drop 800 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Devit-3 Oral Drop | Arm Label: Devit-3 Oral Drop 1000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Devit-3 Oral Drop | Intervention Type: DRUG; Name: Devit-3 Oral Drop; Assigned to Arm(s): Devit-3 Oral Drop 1000 IU, Devit-3 Oral Drop 400 IU, Devit-3 Oral Drop 800 IU
C: Arm Label: Vitamin D3 100,000 IU; Type: EXPERIMENTAL; Interventions: Drug: Experimental: Vitamin D3 100,000 IU | Arm Label: Vitamin D3 12,000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active Comparator: Vitamin D3 12,000 IU | Intervention Type: DRUG; Name: Experimental: Vitamin D3 100,000 IU; Assigned to Arm(s): Vitamin D3 100,000 IU | Intervention Type: DRUG; Name: Active Comparator: Vitamin D3 12,000 IU; Assigned to Arm(s): Vitamin D3 12,000 IU
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Strength Training and Walking Training on Physical Fitness of Patients With Intermittent Claudication
Brief Summary: Background: Muscle atrophy and reduced leg strength are related to exercise intolerance in patients with intermittent claudication (IC), suggesting that strength training (ST) could improve exercise performance in these patients.

Objective: Analyze the effects of ST in walking capacity in patients with IC comparing with walking training (WT) effects.

Intervention: Patients were randomized into ST and WT. Both groups trained twice a week, for 12 weeks, at the same rate of perceived exertion. ST consisted of 3 sets of 10 repetitions of whole body exercises. WT consisted of 15 two-minute bouts of walking intercalated with 2 minutes of resting.

Measurements: Walking capacity, peak VO2, walking economy, ankle brachial index, ischemic window and knee extension strength


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control--Resistance Training | Intervention Type: BEHAVIORAL; Name: Walking Exercise; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Control--Resistance Training; Assigned to Arm(s): 3
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Therapy, Drug: Cilostazol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Drug: Cilostazol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Behavioral: Supervised Exercise Therapy | Intervention Type: DEVICE; Name: Stent; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Therapy; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): 1, 2
C: Arm Label: Strength training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Strength Training | Arm Label: Walking training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Walking Training | Intervention Type: BEHAVIORAL; Name: Walking Training; Assigned to Arm(s): Walking training | Intervention Type: BEHAVIORAL; Name: Strength Training; Assigned to Arm(s): Strength training
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Intervention Type: BEHAVIORAL; Name: Walking Exercise; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Strength Training and Walking Training on Physical Fitness of Patients With Intermittent Claudication
Brief Summary: Background: Muscle atrophy and reduced leg strength are related to exercise intolerance in patients with intermittent claudication (IC), suggesting that strength training (ST) could improve exercise performance in these patients.

Objective: Analyze the effects of ST in walking capacity in patients with IC comparing with walking training (WT) effects.

Intervention: Patients were randomized into ST and WT. Both groups trained twice a week, for 12 weeks, at the same rate of perceived exertion. ST consisted of 3 sets of 10 repetitions of whole body exercises. WT consisted of 15 two-minute bouts of walking intercalated with 2 minutes of resting.

Measurements: Walking capacity, peak VO2, walking economy, ankle brachial index, ischemic window and knee extension strength


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control--Resistance Training | Intervention Type: BEHAVIORAL; Name: Walking Exercise; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Control--Resistance Training; Assigned to Arm(s): 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): 3
C: Arm Label: PTA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous Transluminal Angioplasty (PTA) | Arm Label: SEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Supervised Exercise Programme (SEP) | Arm Label: PTA+SEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Combined Treatment | Intervention Type: PROCEDURE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): PTA | Intervention Type: PROCEDURE; Name: Supervised Exercise Programme (SEP); Assigned to Arm(s): SEP | Intervention Type: PROCEDURE; Name: Combined Treatment; Assigned to Arm(s): PTA+SEP
D: Arm Label: Strength training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Strength Training | Arm Label: Walking training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Walking Training | Intervention Type: BEHAVIORAL; Name: Walking Training; Assigned to Arm(s): Walking training | Intervention Type: BEHAVIORAL; Name: Strength Training; Assigned to Arm(s): Strength training

Answer: D